---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264631"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:42:10.567728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biomea Q3 net loss $16.4M (down 50% YoY); cash $47M; advances icovamenib and BMF-650

## Summary
- Net loss $16.4M for Q3 2025 vs $32.8M in Q3 2024; R&D expenses down ~47% YoY.
- Cash, cash equivalents $47M as of Sep 30, 2025; raised ~$68M in two public offerings extending runway into Q1 2027.
- Icovamenib Phase II COVALENT-111: 1.5% mean HbA1c reduction at Week 52 in severe insulin-deficient T2D patients (p=0.01).
- BMF-650 (oral GLP-1 RA) dosed first patient in Phase I; 28-day weight reduction data expected H1 2026.
- Workforce reduced to ~40 employees as part of operational streamlining.

## SEC filing metadata
- accession: 0001193125-25-264631
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/0001193125-25-264631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/bmea-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264631
- JSON: https://secwatch.observer/filing/0001193125-25-264631.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.